Mapping the genomic landscape of MASLD: A framework for molecular subtyping and precision hepatology [0.03%]
Carlos José Pirola,Silvia Sookoian
Carlos José Pirola
Metabolic dysfunction-associated steatotic liver disease (MASLD) is not merely a hepatic manifestation of systemic metabolic dysregulation, but a central node and active determinant of multi-organ derangement. As a primary cause of cirrhosi...
Clinically actionable genomic and transcriptomic landscape of advanced neuroendocrine neoplasms [0.03%]
Simon Kreutzfeldt,Leonidas Apostolidis,Małgorzata Oleś et al.
Simon Kreutzfeldt et al.
Background: Epithelial neuroendocrine neoplasms (NENs) are a rare and heterogeneous group of malignancies with limited treatment options. Comprehensive molecular characterization may reveal novel therapeutic opportunities...
Rethinking the role of synergy calculations in the next century of drug combination discovery [0.03%]
Christian T Meyer,Yunxing Dai,Amy E Pomeroy et al.
Christian T Meyer et al.
Therapeutic strategies increasingly leverage drug combinations, yet preclinical drug synergy frameworks often hinder, rather than accelerate, the clinical translation of medicinal combinations. To modernize the field of drug combination dis...
Impact of baseline medications on real-world overall survival in immune checkpoint inhibitor-treated patients with cancer in the RADIOHEAD cohort [0.03%]
真实世界程序性死亡受体-l夹心ELISA试剂盒治疗癌症患者的基线用药对抗肿瘤远期生存率的影响——放射组学研究子队列分析
Samantha Stone,Muhammad Zaki Fadlullah,Yuxin Zhao et al.
Samantha Stone et al.
Background: The benefits of immune checkpoint inhibitors (ICIs) observed in clinical trials often fail to translate to patients with cancer treated in a real-world setting. The identification of modifiable or monitorable ...
Ferroptosis in MASLD: From molecular mechanisms to therapeutic opportunities [0.03%]
MASLD中铁死亡：从分子机制到治疗机会
Xiao-Dong Zhou,Qiong-Yue Fan,Giovanni Targher et al.
Xiao-Dong Zhou et al.
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver conditions, ranging from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), advanced fibrosis, and cirrhosis. Ferro...
Is EGFR back? ADCs revive targeted therapy in nasopharyngeal carcinoma [0.03%]
EGFR卷土重来？偶联药物让鼻咽癌靶向治疗重获新生
Hiroaki Kanemura,Hidetoshi Hayashi
Hiroaki Kanemura
MRG003, a novel EGFR-targeted antibody-drug conjugate (ADC), demonstrates significant efficacy in heavily pretreated patients with recurrent or metastatic nasopharyngeal carcinoma. With an objective response rate of 42% and encouraging over...
Phase 3 study results for oral PCSK9 inhibition with enlicitide [0.03%]
口服PCSK9抑制剂Enliticidine三期研究结果
Irina Müller-Kozarez,Ulrich Laufs
Irina Müller-Kozarez
Two large randomized, placebo-controlled phase 3 trials, CORALreef Lipids1 and CORALreef heFH,2 demonstrated that once-daily oral enlicitide lowered LDL cholesterol by approximately 56%-60% on top of background lipid-lowering therapy. Reduc...
Clinical Trial
Med (New York, N.Y.). 2026 Apr 10;7(4):101097. DOI:10.1016/j.medj.2026.101097 2026
Novel immunotherapy response predictor based on blood Temra cell signature [0.03%]
基于血液Temra细胞谱型的新型免疫治疗反应预测因子
Guo Zhao,Shuhang Wang
Guo Zhao
Dong et al. revealed that circulating CX3CR1+ terminally differentiated effector memory (Temra) cells are key predictors of immunotherapy response. A 20-gene Temra transcriptional signature that stratifies responders from non-responders was...
Chronic obstructive pulmonary disease as a double-edged sword-reshaping NSCLC immunotherapy paradigms [0.03%]
慢性阻塞性肺病是一把双刃剑——重塑非小细胞肺癌的免疫治疗模式
Haowei Wang,Tao Jiang
Haowei Wang
Chen et al. demonstrate that NSCLC patients with COPD exhibit superior anti-PD-1 responses through a distinctive immunological mechanism. COPD-driven epithelial remodeling expands CXCL14+ basal-like tumor cells, which orchestrate CXCL9+ mac...
Xinrong Zhang,Vincent Wai-Sun Wong
Xinrong Zhang
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of cirrhosis and hepatocellular carcinoma. Conditional FDA approvals for resmetirom and semaglutide followed positive histological responses in recent trials, but fu...